HETEROCYCLES, Vol. 88, No. 1, 2014, pp. 331 - 346. © 2014 The Japan Institute of Heterocyclic Chemistry Received, 6th June, 2013, Accepted, 4th July, 2013, Published online, 16th July, 2013 DOI: 10.3987/COM-13-S(S)27

DIASTEREOSELECTIVE SYNTHESIS OF 3-FLUORO-2-SUBSTITUTED PIPERIDINES AND PYRROLIDINES^{\dagger}

Paul N. Gichuhi, Masami Kuriyama, and Osamu Onomura*

Graduate School of Biomedical Sciences, Nagasaki University, 1-14, Bunkyomachi, Nagasaki 852-8521, Japan. Email: onomura@nagasaki-u.ac.jp

Abstract – A facile procedure for synthesis of *trans*-3-fluoro-2-substituted piperidines by utilizing electrophilic fluorination of cyclic enamines and Lewis acid mediated nucleophilic substitution has been developed. Also, optically active *trans*-2-allyl-3-fluorinated pyrrolidines have been prepared by utilizing nucleophilic fluorination of hydroxyl group of *trans*-hydroxy-L-proline and Lewis acid mediated diastereoselective allylation as key steps.

INTRODUCTION

N-Heterocycles such as substituted piperidine or pyrrolidines are vast substructures in a great number of biologically active natural products and small molecule pharmaceuticals.¹ Since fluorinated compounds exhibit distinctive biological and physical properties, fluorinated *N*-heterocycles are of great interest in areas such as; material science, agrochemicals, and pharmaceuticals (Figure 1).² To date, both electrophilic and nucleophilic fluorination methods have been developed to furnish fluorinated *N*-heterocycles.^{3,4}



Figure 1. Some examples of fluorinated *N*-heterocycles

[†] Dedicated to Professor Dr. Victor Snieckus on his 77th birthday.

In addition, the nucleophilic additions to *N*-acyliminium ions are powerful methods for synthesis of biologically active *N*-heterocycles.⁵ Also, a large number of methods containing diastereoselective reactions to furnish substituted piperidines and pyrrolidines have been developed.⁶ An example of such addition reaction to *N*-acyliminium ion in which a fluorine atom present on the ring influences the stereochemistry of the adducts is uniquely important. Hence the synthesis of stereo defined fluorinated cyclic amine derivatives with nucleophilic addition to *N*-acyliminium ion has not yet been reported. Herein, we describe a facile synthesis using an electrophilic fluorinating reagent SelectfluorTM 1⁷ utilizing *N*-acyliminium ion precursors to furnish 3-fluorinated derivatives, where the fluorine atom on the ring influences the diastereoselectivities of adducts. The significance of this method is threefold: (Step 1) Preparation of *N*-protected cyclic enamines **4** from corresponding amines **2** using the electrochemical oxidation method⁸ and demethoxylation of **3**.⁹ (Step 2) Electrophilic fluorination of **4** using **1**, which is safe, non-toxic, and easy to handle (Eq. 1).^{10,11} (Step 3) Lewis acid mediated nucleophilic substitution of **5** to give *trans*-substituted derivatives **6** or **7** (Eq. 2).



In addition, a nucleophilic fluorination with XtalFluor- E^{TM} 8¹² of *N*-Cbz-*trans*-4-hydroxy-L-prolinate 9 afforded *cis*-fluoro-L-prolinate 10 which was electrochemically transformed into methoxylated derivative 11. Successive diastereoselective allylation of 11 afforded optically active allylated derivative 12 which was easily transformed into 2*R*-allyl-3*S*-fluoropyrrolidine 13 (Eq. 3).¹³



RESULTS AND DISCUSSION

Preparation of *N*-protected enamines **4a-f** from the respective *N*-protected piperidines and pyrrolidines was achieved according to Shono method which consists of electrochemical methoxylation and successive removal of methanol with up to 97% yield.^{8,9} Next, electrophilic fluorination of substrates **4a-f** using SelectfluorTM **1** afforded 3-fluoro-2-methoxy-*N*-protected piperidine and pyrrolidine derivatives.^{7,10} Namely, addition of **1** to a solution of **4** in acetonitrile/methanol gave **5a-f** in good yields (Table 1).

N PG 4a-f	+ ci + N 1 (1.1	N-F 2BF ₄ equiv)	MeOH/MeO 0 °C to 3 h	CN=1:1	PG 5a-f
Entry	PG	n	Substrate	Product	Yield (%)
1	CO ₂ Me	2	4a	5a	72
2	CO₂Ph	2	4b	5b	74
3	CO₂Ph	1	4c	5c	64
4	Cbz	2	4d	5d	79
5	Cbz	1	4e	5e	72
6	Bz	2	4f	5f	65

Table 1. Fluoromethoxylation of cyclic enamines 4a-f

We envisaged that upon treatment of **5** with some Lewis acids, the *N*-acyliminium ions was generated and readily trapped by the carbon nucleophiles resulting to the desired products with fluorine atom influencing the diastereoselectivities.^{13,14} To our delight, when compounds **5** were treated with some Lewis acids in CH₂Cl₂, the allylation using allyltrimethylsilane proceeded satisfactorily to give allylated products **6** in good yields (Table 2). TiCl₄ or BF₃·OEt₂ mediated allylation of 3-fluoro-2-methoxy-*N*-methoxycarbonylpiperidine **5a** smoothly proceeded to afford the allylated product **6a** in high yields with moderate diastereoselectivities (entries 1 and 2). For allylation of *N*-phenyloxycarbonylated piperidine **5b**, the higher diastereoselectivity was achieved by using TiCl₄ affording 58% de and 81% yield compared with BF₃·OEt₂ (entries 3 and 4). Although TiCl₄ did not result to the allylated product for *N*-benzyloxycarbonylated piperidine **5d**, using BF₃·OEt₂ gave 58% de and 87% yield (entries 6 and 7).¹⁵ On the other hand, SnCl₄ did not lead to any improvement on the de value of **6d** (entry 8). In addition, BF₃·OEt₂ mediated allylation of pyrrolidine derivatives **5c**,**e** proceeded to afford substituted products **6c**,**e** in high yields with low diastereoselectivities (entries 5 and 9).

Next we focused on cyanation of **5**. When compounds **5a**,**b**,**d** were treated with trimethylsilyl cyanide in the presence of TiCl₄, the desired product was formed in high yields and moderate diastereoselectivities as shown in Table 3 (entries 1-3). Also, 2-cyano-3-fluoro-*N*-benzyloxycarbonylpiperidine **7d** was formed with a higher de of 58% and yield of 84% when mediated by BF₃·OEt₂ as the Lewis acid of choice (entry 4). SnCl₄ did not lead to an improvement of the de and the yield of **7d** (entry 5).

PG 5	⊂OMe + ∕∕∕ (3.	SiMe ₃ Lew in Cl 0 equiv) –78	is acid (1.1 equiv) H ₂ Cl ₂ °C to rt, 3 h	F N PG trans-6 (major)	$+ \underbrace{\begin{pmatrix} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	nor)
Entry	PG	n	Lewis acid	Product	Vield (%)	$De (%)^{a}$
1	CO₂Me	2	TiCl	6a	89	44
2	CO ₂ Me	2	BF ₃ ·OEt ₂	6a	76	40
3	CO ₂ Ph	2	TiCl ₄	6b	81	58
4	CO₂Ph	2	$BF_3 \cdot OEt_2$	6b	69	42
5	CO₂Ph	1	BF ₃ ·OEt ₂	6c	82	14
6	Cbz	2	TiCl ₄	6d	0	-
7	Cbz	2	BF ₃ ·OEt ₂	6d	87	58
8	Cbz	2	SnCl ₄	6d	68	48
9	Cbz	1	BF ₃ ·OEt ₂	6e	79	26

 Table 2. Synthesis of 2-allyl-3-fluoropiperidine derivatives 6

^a Determined by ¹H NMR and/or ¹⁹F NMR at 50 °C.

Table 3. Synthesis	of 2-cyano-3	3-fluoropiperidine	derivatives 7
2	2	1 1	

	F N PG	$Me_3SiCN (3.0 equiv)$ Lewis acid (1.1 equiv) in CH_2Cl_2 –78 °C to rt, 3 h) v) PG	+ N ^{''''} CN PG	
	5		trans- 7	cis- 7	
Entry	PG	Lewis acid	Product	Yield (%)	De (%) ^a
1	CO ₂ Me	TiCl ₄	7a	89	48
2	CO₂Ph	TiCl ₄	7b	83	50
3	Cbz	TiCl ₄	7d	76	50
4	Cbz	BF ₃ ·OEt ₂	7d	84	58
5	Cbz	SnCl ₄	7d	62	34

^a Determined by ¹H NMR and/or ¹⁹F NMR at 50 °C.

Relative stereoconfigurations for **6** and **7** were speculated by the NOESY studies for **6d** and the HMBC studies¹⁶ for **7d**. Diastereomers of **6d** or **7d** were separable by silica gel PTLC to afford major isomer and minor isomer, respectively. The NOESY spectroscopy for major isomer of **6d** showed correlations, while the NOESY spectroscopy for minor isomer of **6d** did not show the correlation. Accordingly, it was determined that major isomer was *trans*-**6d** and minor isomer was *cis*-**6d**. Similarly separated major isomer for **7d** was determined as *trans* configuration (Figure 2).



Figure 2. NOESY for 6d and HMBC for 7d

We next focused on the synthesis of optically active 2-allyl-3-fluoropyrrolidine starting from *N*-Cb*ztrans*-4-hydroxy-L-prolinate 9.¹⁷ Deoxofluorination of 9 was achieved by utilizing XtalFluor- E^{TM} 8 as the reagent of choice.¹² The fluorination of the hydroxyl group at the 4-position proceeded in an inversion manner to give the desired compound 10 in 82% yield.^{12,18} Electrochemical oxidation of 10 afforded 4fluoro-5-methoxy-L-proline derivative 11 in 74% yield (Eq. 4).



The allylation of **11** using 2.0 equiv of Lewis acids¹⁹ was successfully achieved affording compound **12** (Eq. 5).¹³ In the case of *N*-benzyloxycarbonylprolinate **11**, the allylation mediated by TiCl₄ resulted to good yield and de. Using BF_3 ·OEt₂ afforded **12** in higher yield and de (entry 2), while the use of SnCl₄ afforded low yield and de of **12**.



Hydrolysis, successive decarboxylative methoxylation, and reductive demethoxylation¹³ of **12** prepared by using BF_3 ·OEt₂ proceeded smoothly without purification of intermediate **14** to give 2-allyl-3*S*-fluoropyrrolidine **13** (Eq. 6).



Comparing HPLC pattern of 13 with that of 6e (*trans/cis*=63:37) showed that the relative stereoconfiguration of 13 was majorly *trans* (82% de) and its absolute stereoconfiguration was $2R_{,3S}$.

CONCLUSION

In conclusion, a facile procedure for synthesis of *trans*-3-fluoro-2-substituted piperidines and optically active *trans*-2-allyl-3-fluorinated pyrrolidine which can be used as precursors for new drugs in pharmaceuticals has been developed. This was achieved by utilizing facile electrochemical oxidation and electrophilic or nucleophilic fluorination. Additionally, mild conditions and practical convenience will make this method a valuable synthetic tool in organic chemistry.

EXPERIMENTAL

General: All commercial materials, reagents and solvents, were used without further purification unless otherwise stated. Electrochemical reactions were carried out by the use of DC power supply (GP 050-2) of Takasago Seikakusho in an undivided glass cell by using platinum plate electrodes (10 x 20 mm), graphite electrodes (50 x 12 x 2 mm). ¹H NMR spectra were measured at 500 and 400 MHz with TMS as an internal standard at 50 °C, ¹⁹F NMR spectra were measured at 376 MHz with CFCl₃ used as the internal standard at 50 °C. ¹³C NMR spectra were measured at 100MHz on JEOL JNM-AL 400MHZ. IR spectra were obtained on Shimadzu FTIR-8100A. High resolution mass spectra were recorded on a JEOL JMS-700N instrument using electron ionization (EI) mass spectrometry. Melting points were measured with micro melting point apparatus (Yanaco). Flash column chromatography was performed using silica gel 60 (230-400 mesh, Nacalai tesque) with the indicated solvents. Thin-layer chromatography was performed using 0.25 mm silica gel plates (Merck). Specific optical rotations were recorded on JASCO DIP-1000 digital polarimeter.

General procedure for the preparation of N-protected enamines 4a-f

The substrates **4a-i** were prepared from the respective *N*-protected piperidine and pyrrolidines according to previously reported methods.^{8,9} Compounds **4a**,⁸ **4b**,²⁰ **4c**,²¹ **4d**,²² **4e**,⁹ and **4f**²³ are known compounds and their spectroscopic data is available in literature.

General procedure for the fluorination of N-protected enamines 4a-i using Selectfluor

To the substrates **4a-f** (1.0 mmol) dissolved in 3 mL of MeCN/MeOH (1:1) under a nitrogen atmosphere, Selectfluor (1.1 mmol) was added at 0 °C stirring the mixture for 1 h. The temperature of the mixture was then gradually allowed to rise to room temperature and the reaction was monitored using TLC for over 2 h. Water (5 mL) was added and the mixture extracted using CH_2Cl_2 (5 x 10 mL). The combined organic layer was dried by anhydrous Na₂SO₄. The crude product was purified by column chromatography on silica gel (*n*-hexane/EtOAc 4:1) to give the desired product **5a-f**.

3-Fluoro-2-methoxy-N-methoxycarbonylpiperidine (5a)

Colorless oil; ¹H NMR (CDCl₃) δ 1.42-1.65 (m, 1H), 1.73-2.03 (m, 3H), 2.85-2.99 (m, 1H), 3.30 and 3.36 (2s, 3H), 3.74 and 3.75 (2s, 3H), 3.81-4.03 (m, 1H), 4.35-4.52 and 4.61 (m and d, *J*=46.4 Hz, 1H), 5.20-5.55 (m, 1H); ¹³C NMR (CDCl₃) δ 18.7 and 23.2 (2s), 24.1 and 24.2 (2s), 37.3 and 37.9 (2s), 52.4 and 52.5 (2s), 54.6 and 55.1 (2s), 82.2 and 82.5 (2s), 85.8 and 88.6 (2d, *J*=170.6 and 183.9 Hz), 156.7 and 155.9 (2s); ¹⁹F NMR (CDCl₃) δ -191.2 (br s, 0.67F), -183.5 (d, *J*=47.3 Hz, 0.33F); IR (neat) 2953, 1701, 1440, 1412, 1369, 1261, 1163, 1086, 962, 770 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₈H₁₄FNO₃ [M⁺] 191.0958, found 191.0941.

3-Fluoro-2-methoxy-N-phenyloxycarbonylpiperidine (5b)

Mp 76-78 °C; ¹H NMR (CDCl₃) δ 1.52-1.68 (m, 1H), 1.75-2.07 (m, 3H), 3.05 (br s, 1H), 3.31-3.53 (m, 3H), 3.96-4.10 (m, 1H), 4.53 and 4.67 (br d and d, *J*=47.6 and 47.6 Hz, 1H), 5.51-5.62 (m, 1H), 7.09-7.36 (m, 5H); ¹³C NMR (CDCl₃) δ 23.82-24.38 (m), 25.50 (br s), 38.19 (br s), 52.75-56.04 (m), 82.98 (br s), 84.88-86.79 (m), 121.06-121.76 (m, 2C), 124.67-125.60 (m), 128.75-129.40 (m, 2C), 150.89-151.35 (m), 153.61 (s); ¹⁹F NMR (CDCl₃) δ –191.57 (t, *J*=45.1 Hz, 0.40F), –183.8 (t, *J*=47.1 Hz, 0.60F); IR (neat) 2945, 1717, 1495, 1410, 1381, 1369, 1260, 1198, 1161, 1069, 1024, 968, 748 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₃H₁₆FNO₃ [M⁺] 253.1114, found 253.1127.

3-Fluoro-2-methoxy-N-phenyloxycarbonylpyrrolidine (5c)

Colorless oil; ¹H NMR (CDCl₃) δ 2.20-2.31 (m, 2H), 3.48 and 3.58 (2s, 3H), 3.73-3.81 (m, 2H), 4.89-5.04 (m, 1H), 5.24-5.33 (m, 1H), 7.13-7.25 (m, 3H), 7.34-7.38 (m, 2H); ¹³C NMR (CDCl₃) δ 28.17-29.96 (m), 41.37-46.30 (m), 56.04-57.97 (m), 86.39 (s), 91.49-95.59 (m), 121.92 (br s), 125.87 (s, 2C), 129.66 (s, 2C), 151.01 (2s), 153.02-154.84 (m); ¹⁹F NMR (CDCl₃) δ –200.3- –201.5 (m, 0.37F), –186.9- –188.2 (m, 0.63F); IR (neat) 2936, 1721, 1593, 1495, 1456, 1387, 1371, 1204, 1163, 1099, 1042, 957, 731 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₂H₁₄FNO₃ [M⁺] 239.0958, found 239.0958.

N-Benzyloxycarbonyl-3-fluoro-2-methoxypiperidine (5d)

Colorless oil; ¹H NMR (CDCl₃) δ 1.40-1.54 (m, 1H), 1.69-2.05 (m, 3H), 2.89-2.95 (m, 1H), 3.25-3.62 (m, 3H), 3.68-4.00 (m, 1H), 4.33-4.50 and 4.59 (m and d, *J*=48.1 Hz, 1H), 5.06-5.27 (m, 2H), 5.46 (br s, 1H), 7.23-7.41 (m, 5H); ¹³C NMR (CDCl₃) δ 18.9 and 23.3 (2s), 24.2 and 24.4 (2s), 37.5 and 38.1 (2s), 54.8 and 55.1 (2s), 67.2 and 67.4 (2s), 82.3 and 82.6 (2s), 85.9 and 88.7 (2s), 127.9 (s), 128.1 (s), 128.0 (s), 128.3 (s), 128.5 and 128.6 (2s), 136.2 and 136.5 (2s), 155.2 and 155.9 (2s); ¹⁹F NMR (CDCl₃) δ -191.37(s, 0.50F), -183.67 (s, 0.50F); IR (neat) 2947, 1697, 1447, 1418, 1258, 1070, 962 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₄H₁₈FNO₃ [M⁺] 267.1271, found 267.1257.

N-Benzyloxycarbonyl-3-fluoro-2-methoxypyrrolidine (5e)

Colorless oil; ¹H NMR (CDCl₃) δ 2.03-2.15 (m, 2H), 3.18-3.47 (m, 4H), 3.57 (br s, 1H), 4.68-4.88 and 4.81 (m and d, *J*=52.4 Hz, 1H), 4.95-5.25 (m, 3H), 7.19-7.28 (m, 5H); ¹³C NMR (CDCl₃) δ 29.82 (s), 41.55 (s), 43.71 and 45.62 (2s), 55.60 and 56.16 (2s), 86.55 (s), 91.65 (s), 127.72-128.58 (m, 5C), 136.19-136.35 (m), 155.17-155.79 (m); ¹⁹F NMR (CDCl₃) δ –201.25 and –200.32 (2d, *J*=41.0, 51.9 Hz, 0.19F), –188.03 and –187.10 (2s, 0.81F); IR (neat) 2947, 1705, 1449, 1404, 1341, 1279, 1213, 1177, 1096, 1076, 959, 772 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₃H₁₆FNO₃ [M⁺] 253.1114, found: 253.1120.

N-Benzoyl-3-fluoro-2-methoxypiperidine (5f)

Colorless oil; ¹H NMR (CDCl₃) δ 1.45-2.23 (m, 4H), 2.94-3.52 (m, 4H), 4.15-6.10 (m, 3H), 7.39-7.48 (m, 5H); ¹³C NMR (CDCl₃) δ 19.31 (br s), 24.62-25.03 (m), 36.22 (m), 54.85 and 55.6 (2s), 85.74-88.01 (m),

89.87 (br s), 127.23-127.80 (m, 2C), 128.68-128.89 (m, 2C), 130.03 and 130.42 (2s), 135.55 and 135.76 (2s), 171.65 and 172.38 (2s); ¹⁹F NMR (CDCl₃) δ –191.24 (br s, 0.29F), –183.23 and –184.09 (2br s, 0.71F); IR (neat) 2945, 1641, 1412, 1352, 1301, 1273, 1069, 1045, 968, 702 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₃H₁₆FNO₂ [M⁺] 237.1165, found 237.1151.

General procedure for the preparation of 2-allyl-3-fluoro-N-protected cyclic amine derivatives 6a-e

The substrate compound **5** (1.0 mmol) and allyltrimethylsilane (3.0 mmol) were dissolved in dry CH_2Cl_2 (3 mL) at -78 °C, under nitrogen atmosphere. 1M TiCl₄ in CH_2Cl_2 (1.1 mmol) was added dropwise via syringe. The reaction was allowed to warm to room temperature over 3 h, progress monitored by TLC. After completion, the reaction mixture was quenched with (5 mL) of saturated aqueous NaHCO₃ solution. The aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL) and the combined organic layer washed with saturated aqueous NaCl (10 mL) and dried over anhydrous Na₂SO₄. The organic layer was evaporated in vacuo, which was further purified by column chromatography on silica gel (*n*-hexane/EtOAc 8:1) as eluent giving a mixture of diastereoisomers compound **6**.

2-Allyl-3-fluoro-N-methoxycarbonylpiperidine (6a) (44% de)

Colorless oil; ¹H NMR (CDCl₃) δ 1.34-1.52 (m, 1H), 1.58-1.78 (m, 2H), 1.80-1.97 (m, 1H), 2.13-2.39 (m, 2H), 2.68 (td, *J*=13.4, 3.1 Hz, 0.72H), 2.78-2.83 (m, 0.28H), 3.48-3.72 (m, 3H), 3.87 (d, *J*=12.2 Hz, 0.72H), 4.01 (d, *J*=9.8 Hz, 0.28H), 4.45-4.51 (m, 1H), 4.57-4.63 (m, 1H), 4.94-5.05 (m, 2H), 5.61-5.72 (m, 1H); ¹³C NMR (CDCl₃) δ 19.65 (s), 24.96-25.24 (m), 25.90 (s), 33.63 and 33.72 (2s), 38.09 and 39.15 (2s), 53.01-54.12 (m), 87.98 and 89.74 (2d, *J*=184.0 and 170.5 Hz), 117.72 and 118.24 (2s), 134.29 and 134.72 (2s), 156.95 and 157.27 (2s); ¹⁹F NMR (CDCl₃) δ –182.45 (br s, 0.28F), –181.51 (d, *J*=48.8 Hz, 0.72F); IR (neat) 2953, 1694, 1449, 1408, 1366, 1310, 1190, 1152, 1034, 959, 916, 766 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₀H₁₆FNO₂ [M⁺] 201.1165, found 201.1163.

2-Allyl-3-fluoro-N-phenyloxycarbonylpiperidine (6b) (58% de)

Mp 80-81 °C; ¹H NMR (CDCl₃) δ 1.57-1.72 (m, 2H), 1.73-1.91 (m, 1H), 1.87-2.15 (m, 1H), 2.34-2.58 (m, 2H), 4.09 (d, *J*=13.7 Hz, 0.79H), 4.22 (d, *J*=12.2 Hz, 0.21H), 4.56-4.87 (m, 2H), 4.99-5.25 (m, 2H), 5.15-5.66 (m, 1H), 5.70-5.95 (m, 1H), 7.01-7.13 (m, 2H), 7.13-7.21 (m, 1H), 7.27-7.39 (m, 2H); ¹³C NMR (CDCl₃) δ 19.24 (s), 24.79 and 24.57 (2s), 33.24 and 33.33 (2s), 38.08 (br s), 53.84 (br s), 86.72 and 88.71 (2s), 115.73 (s), 118.0 (br s), 119.08 (s), 121.73 (s), 125.15 (s), 129.19 (s), 133.56 (s), 151.61 (s), 154.23 (s); ¹⁹F NMR (CDCl₃) δ –178.91 and –179.55 (2b s, 1F); IR (neat) 2949, 1709, 1643, 1593, 1495, 1412, 1356, 1310, 1240, 1196, 1161, 1140, 1040, 1024, 991, 957, 743 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₅H₁₈FNO₂ [M⁺] 263.1322, found 263.1324.

2-Allyl-3-fluoro-N-phenyloxycarbonylpyrrolidine (6c) (14% de)

Colorless oil; ¹H NMR (CDCl₃) & 1.79-2.67 (m, 4H), 2.81 and 3.42-4.28 (br s and m, 3H), 4.83-5.26 (m,

3H), 5.68-5.87 (m, 1H), 7.06-7.17 (m, 3H), 7.27-7.35 (m, 2H); ¹³C NMR (CDCl₃) δ 28.54-31.62 (m), 35.72 and 36.78 (2br s), 44.65 (s), 62.11 and 63.99 (2br s), 91.86-94.26 (m), 117.88 (s), 118.15 (br s), 121.58 (s), 125.19 (s), 129.11 and 129.19 (2s), 133.48 (br s), 134.14 and 134.16 (2s), 151.33 and 151.35 (2s), 153.09 and 153.17 (2s); ¹⁹F NMR (CDCl₃) δ –193.17 and –193.84 (2br s, 0.57F), –176.21- –175.20 (m, 0.43F); IR (neat) 2949, 1717, 1641, 1593, 1494, 1389, 1192, 1070, 1022, 918, 754, 739 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₄H₁₆FNO₂ [M⁺] 249.1165, found 249.1162.

2-Allyl-N-benzyloxycarbonyl-3-fluoropiperidine (6d) (58% de)

Colorless oil; ¹H NMR (CDCl₃) δ 1.42-1.64 (m, 2H), 1.68-1.83 (m, 1H), 1.88-2.05 (m, 1H), 2.35-2.47 (m, 2H), 2.78 (t, *J*=13.4 Hz, 0.79H), 2.88 (t, *J*=13.2 Hz, 0.21H), 4.00 (br d, *J*=13.9 Hz, 0.79H), 4.14 (br d, *J*=13.2 Hz, 0.21H), 4.50-4.72 (m, 2H), 4.95-5.20 (m, 4H), 5.62-5.78 (m, 1H), 7.33 (s, 5H); ¹³C NMR (CDCl₃) δ 23.71 (s), 25.59 and 25.78 (2s), 28.88 (s), 37.96 and 39.01 (2s), 53.67 and 53.92 (2s), 67.46 and 67.64 (2s), 88.25 and 90.06 (2s), 117.63 and 118.11 (2s), 128.1-28.92 (m, 5C), 134.05 and 134.59 (2s), 137.14 and 137.40 (2s), 156.07 (s); ¹⁹F NMR (CDCl₃) δ –181.48 (d, *J*=48.9 Hz, 1F); IR (neat) 2949, 1692, 1423, 1350, 1248, 1148, 1069, 1028, 1001, 959, 733 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₆H₂₀FNO₂ [M⁺] 277.1478, found 277.1458.

Further purification of a mixture of *cis*- and *trans*-6d by PTLC afforded *cis*-6d and *trans*-6d.

cis-2-Allyl-N-benzyloxycarbonyl-3-fluoropiperidine (cis-6d) (less polar)

Colorless oil; ¹H NMR (CDCl₃) δ 1.44-1.62 (m, 1H), 1.69-1.85 (m, 2H), 1.89-2.05 (m, 1H), 2.35-2.45 (m, 2H), 2.88 (t, *J*=13.4 Hz, 1H), 4.14 (d, *J*=13.7 Hz, 1H), 4.52-4.71 (m, 2H), 5.09 (br s, 1H), 4.99-5.03 (m, 1H), 5.10-5.17 (m, 2H), 5.7 (d, *J*=7.3 Hz, 1H), 7.27-7.38 (m, 5H); ¹³C NMR (CDCl₃) δ 23.66 and 23.76 (2s), 24.82 and 25.04 (2s), 28.88 (s), 37.96 (s), 53.67 and 53.92 (2s), 67.46 and 67.64 (2s), 88.25 and 90.06 (2s), 117.63 and 118.11 (2s), 128.15-128.86 (m, 5C), 134.05 and 134.59 (2s), 137.14 and 137.40 (2s), 156.07 (s); ¹⁹F NMR (CDCl₃) δ –180.78 (d, *J*=45.7 Hz, 1F).

trans-2-Allyl-N-benzyloxycarbonyl-3-fluoropiperidine (trans-6d) (polar)

Colorless oil; ¹H NMR (CDCl₃) δ 1.49-1.64 (m, 2H), 1.72-1.83 (m, 1H), 1.88-2.00 (m, 1H), 2.34-2.44 (m, 2H), 2.77 (t, *J*=13.3 1H), 3.99 (d, *J*=13.7 Hz, 1H), 4.55 (dt, *J*=10.9, 5.3 Hz, 1H), 4.51-4.59 (m, 1H), 4.61-4.70 (m, 1H), 4.98 (d, *J*=10.0 Hz, 1H), 5.06 (d, *J*=17.3 Hz, 1H), 5.09-5.16 (m, 2H), 5.70 (d, *J*=7.32 Hz, 1H), 7.33 (m, 5H); ¹³C NMR (CDCl₃) δ 23.71 (s) 25.68 (s), 28.88 (s), 37.96 (s), 53.67 and 53.92 (2s), 67.46 and 67.64 (2s), 88.25 and 90.06 (2s), 117.63 and 118.11 (2s), 126.11-130.61 (m, 5C), 133.10 (s), 136.36 (s), 156.07 (s); ¹⁹F NMR (CDCl₃) δ -181.52 (d, *J*=48.9 Hz, 1F).

2-Allyl-N-benzyloxycarbonyl-3-fluoropyrrolidine (6e) (26% de)

Colorless oil; ¹H NMR (CDCl₃) δ 1.62-2.40 (m, 4H), 3.16-4.10 (m, 3H), 4.83 (dd, *J*=52.4, 2.2 Hz, 0.63H), 4.87 (dd, *J*=52.8, 2.8 Hz, 0.37H), 4.96 and 5.00 (2d, *J*=3.4 and 3.4 Hz, 1H), 5.02-5.11 (m, 1H), 5.12-5.21

(m, 2H), 5.62-5.92 (m, 1H), 7.27-7.38 (m, 5H); ¹³C NMR (CDCl₃) δ 29.02 and 30.05 (2br s), 31.08 and 31.30 (2s), 44.50 and 44.52 (2s), 61.53 and 63.69 (2br s), 66.88 (s), 90.34 and 91.86 (2s), 117.60 (s), 117.96 (s), 127.78 (s), 127.89 and 127.95 (2s), 128.42 and 128.44 (2s), 133.55 (s), 134.29 and 134.31 (2s), 136.79 (s), 154.57 and 154.68 (2s); ¹⁹F NMR (CDCl₃) δ –186.96 and –187.89 (2br s, 0.63F), –176.07 and –175.46 (2br s, 0.37F); IR (neat) 2953, 1701, 1447, 1406, 1340, 1279, 1211, 1179, 1098, 1078, 1053, 959, 735 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₅H₁₈FNO₂ [M⁺] 263.1322, found 263.1313. HPLC YMC-Pack SIL column; 150 mm x 4.6 mm ϕ ; *n*-hexane/2-propanol 50:1, wavelength 254 nm, flow rate: 1.0 mL/min, retention time: 3.8 min (37%), 5.6 min (63%).

General procedure for the preparation of 2-cyano-3-fluoro-N-protected cyclic amine derivatives 7a-d

The substrate compound **5** (1.0 mmol) and trimethylsilyl cyanide (3.0 mmol) were dissolved in dry CH_2Cl_2 (3 mL) at -78 °C, under nitrogen atmosphere. 1M TiCl₄ in CH_2Cl_2 (1.1 mmol) was added dropwise via syringe. The reaction was allowed to warm to room temperature, then quenched with saturated aqueous NaHCO₃ (5 mL). The aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL) and the combined organic layer washed with saturated aqueous NaCl (10 mL) and dried over anhydrous Na₂SO₄. The organic layer was evaporated in vacuo, which was further purified by column chromatography on silica gel (*n*-hexane/EtOAc 8:1) as eluent giving a mixture of diastereoisomers compound 7. The same procedure was repeated for BF₃·OEt₂ and SnCl₄.

2-Cyano-3-fluoro-N-methyloxycarbonylpiperidine (7a) (48% de)

Colorless oil; ¹H NMR (CDCl₃) δ 1.51-1.54 (m, 1H), 1.83-1.92 (m, 2H), 2.10-2.30 (m, 1H), 2.96 (td, *J*=13.4, 2.7 Hz, 0.74H), 3.05 (br t, *J*=13.4 Hz, 0.26H), 3.77 (s, 3H), 4.06 (br d, *J*=12.9 Hz, 0.74H), 4.19 (br d, *J*=11.2 Hz, 0.26H), 4.42-4.60 (m, 0.74H), 4.85 (br d, *J*=46.2 Hz, 0.26H), 5.43 and 5.53 (2br s, 1H); ¹³C NMR (CDCl₃) δ 22.31 (s), 25.45 and 27.00 (2s), 40.34 (s), 48.33 and 48.61 (2s), 53.45 (s), 85.80 and 87.63 (2s), 114.21 (s), 154.86 (s); ¹⁹F NMR (CDCl₃) δ -186.45 (br s, 0.26F), -178.76 (d, *J*=47.3 Hz, 0.74F); IR (neat) 2959, 1707, 1447, 1404, 1366, 1306, 1261, 1202, 1109, 1042, 980, 932, 903, 869, 733, 702 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₈H₁₁FN₂O₂ [M⁺] 186.0805, found 186.0802.

2-Cyano-3-fluoro-N-phenyloxycarbonylpiperidine (7b) (50% de)

Mp 79-81°C; ¹H NMR (CDCl₃) δ 1.55-1.70 (m, 1H), 1.90-2.05 (m, 2H), 2.15-2.35 (m, 1H), 3.12 and 3.20 (2br s, 1H), 4.22 and 4.34 (2d, *J*=12.9 and 13.9 Hz, 1H), 4.54-4.72 (m, 0.75H), 4.93 (d, *J*=45.4 Hz, 0.25H), 5.56 (d, *J*=10.4 Hz, 0.25H), 5.65 (d, *J*=5.6 Hz, 0.75H), 7.10-7.17 (m, 2H), 7.22-7.29 (m, 1H), 7.36-7.33 (m, 2H); ¹³C NMR (CDCl₃) δ 25.46 and 25.66 (2s), 27.03 and 27.21 (2s), 41.11 (br s), 48.72 (br s), 84.69 and 86.56 (2s), 114.39 (s), 121.43-121.77 (m, 2C), 125.97-126.25 (m), 129.46-129.72 (m, 2C), 151.06 and 151.19 (2s), 152.04 (s); ¹⁹F NMR (CDCl₃) δ -186.20 and -186.19 (2s, 0.25F), -179.65 (br d, *J*=45.6 Hz, 0.75F); IR (neat) 2959, 1717, 1593, 1494, 1456, 1408, 1348, 1252, 1196, 1070, 1026,

974, 872, 733 cm⁻¹. HR-MS [EI (+)]: m/z calcd for C₁₃H₁₃FN₂O₂ [M⁺] 248.0961, found 248.0960.

N-Benzyloxycabonyl-2-cyano-3-fluoropiperidine (7d) (50% de)

Colorless oil; ¹H NMR (CDCl₃) δ 1.43-2.04 (m, 4H), 3.08 (t, *J*=13.5 Hz, 0.25H), 3.16 (t, *J*=10.8 Hz, 0.75H), 3.83 (d, *J*=12.9 Hz, 0.25H), 3.94 (d, *J*=12.5 Hz, 0.75H), 4.45-4.55 (m, 0.25H), 4.66 (d, *J*=46.8 Hz, 0.75H), 5.14 (s, 2H), 5.77 (d, *J*=2.8 Hz, 0.75H), 5.91 (s, 0.25H), 7.34 (s, 5H); ¹³C NMR (CDCl₃) δ 18.60 (s), 22.81 and 23.73 (2s), 37.93 (s), 38.59 (s), 67.55 and 67.69 (2s), 85.85 and 87.56 (2s), 127.98 (s, 2C), 128.07 (s), 128.23 and 128.31 (2s), 128.64 (s, 2C), 136.32 and 136.43 (2s), 154.89 (s); ¹⁹F NMR (CDCl₃) δ -189.83 (t, *J*=48.8 Hz, 0.75F), -183.46 (d, *J*=44.3 Hz, 0.25F); IR (neat) 2959, 1701, 1414, 1344, 1312, 1254, 1155, 1047, 974, 874, 731 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₄H₁₅FN₂O₂ [M⁺] 262.1118, found 262.1120.

Further purification of a mixture of *cis*- and *trans*-7d by PTLC afforded *cis*-7d and *trans*-7d.

cis-N-Benzyloxycabonyl-2-cyano-3-fluoropiperidine (cis-7d) (less polar)

Colorless oil; ¹H NMR (CDCl₃) δ 1.42-1.61 (m, 1H), 1.76-1.95 (m, 2H), 2.09-2.27 (m, 1H), 2.97 (td, *J*=13.3, 2.7 Hz, 1H), 4.09 (br d, *J*=13.2 Hz, 1H), 4.42-4.60 (m, 1 H), 5.17 (s, 2H), 5.55 (br s, 1H), 7.32-7.38 (m, 5H); ¹³C NMR (CDCl₃) δ 19.62 (s), 27.76 (s), 35.45 (s), 39.30 (s), 58.08 and 58.63 (2s), 67.87 (s), 87.57 (s), 118.62 (s), 128.49 (s, 2C), 128.60 (s), 129.16 (s), 134.37 and 137.76 (2s), 156.79 (s); ¹⁹F NMR (CDCl₃) δ –183.40 (d, *J*=47.0 Hz, 1F).

trans-N-Benzyloxycabonyl-2-cyano-3-fluoropiperidine (trans-7d) (polar)

Colorless oil; ¹H NMR (CDCl₃) δ 1.49-1.59 (m, 2H), 1.87-2.04 (m, 2H), 3.07 (t, *J*=12.5 Hz, 1H), 4.21 (br d, *J*=12.2 Hz, 1H), 4.86 (d, *J*=45.4 Hz, 1H), 5.20 (s, 2H), 5.47 (br s, 1H), 7.35 (s, 5H); ¹³C NMR (CDCl₃) δ 18.29 (s), 20.78-26.17 (m, 2C), 28.54-28.97 (m), 35.65-40.83 (m), 67.01-67.52 (m), 85.56 (s), 125.31-131.34 (m, 5C), 133.93-138.02 (m), 152.89-157.42 (m); ¹⁹F NMR (CDCl₃) δ –188.84 (d, *J*=47.3 Hz, 1F).

Preparation of methyl N-benzyloxycarbonyl-cis-4-fluoro-L-prolinate (10)

N-Benzyloxycarbonyl-*trans*-4-hydroxy-L-prolinate (9) was prepared from *trans*-4-hydroxy-L-proline according to literature method in quantitative yield.^{17,24} Compound 9 was transformed into *N*-benzyloxycarbonyl-*cis*-4-fluoro-L-prolinate 10 according to literature method using XtalFluor-E 8 in 82% yield.²⁵

Methyl N-benzyloxycarbonyl-cis-4-fluoro-L-prolinate (10)

 $[\alpha]_D^{27}$ –45.0 (c 1.78, CH₂Cl₂).

Procedure for electrochemical oxidation of 10

The substrate (1.0mmol) and Et_4NBF_4 (0.1 mmol) were placed in a beaker type cell containing a stirring bar. MeOH and MeCN (1:4) were added and the mixture stirred at 0 °C. The graphite anode and platinum cathodes were fitted and 2.7 Fmol⁻¹ of current was passed through. The reaction mixture was evaporated

to eliminate methanol. Water was added and the mixture was then extracted with EtOAc and the combined organic layer dried using anhydrous MgSO₄ and filtered. The solvent was removed in vacuo and the resulting concentrate purified by silica gel chromatography to afford 4-fluoro-5-methoxy-L-prolinate **11** in 74% yield.

Methyl (2S,4S)-N-benzyloxycarbonyl-4-fluoro-5-methoxy-L-prolinate (11)

Yellow oil; ¹H NMR (CDCl₃) δ 2.23-2.46 (m, 1H), 2.52 (dd, *J*=18.7, 15.0 Hz, 1H), 3.27-3.95 (m, 6H), 4.50-4.66 (m, 1H), 5.14 (t, *J*=4.3 Hz, 1H), 5.16-5.23 (m, 2H), 5.27 (t, *J*=4.3 Hz, 1H), 7.19-7.35 (m, 5H); ¹³C NMR (CDCl₃) δ 29.32 and 29.67 (2s), 36.34-37.87 (m), 51.80 (s), 52.29-53.83 (m), 57.63 and 57.83 (2s), 67.32 and 67.54 (2s), 91.08 and 92.32 (2d, *J*=356.2 and 356.0 Hz), 127.93-128.82 (m, 5C), 136.55 (s), 154.57 (br s), 171.73 (br s); ¹⁹F NMR (CDCl₃) δ -173.68 (br s, 1F); IR (neat) 2955, 1755, 1703, 1414, 1348, 1263, 1206, 1167, 1113, 1003, 957, 916, 735 cm⁻¹; HR-MS [EI (+)]: *m/z* calcd for C₁₅H₁₈FNO₅ [M⁺] 311.1169, found; 305.1167.

Preparation of methyl N-benzyloxycarbonyl -5-allyl-4-fluoro-L-prolinate (12)

To a mixture of **11** (1.0 mmol) and allyltrimethylsilane (3.0 mmol) in dry CH_2Cl_2 (3 mL) was added dropwise BF₃·OEt₂ (2.0 mmol) at -78 °C under nitrogen atmosphere. The reaction was allowed to warm to room temperature over 12 h. The reaction mixture was quenched with saturated aqueous NaHCO₃ (5 mL). The aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL) and the combined organic layer washed with saturated aqueous NaCl (10 mL) and dried over anhydrous Na₂SO₄. The organic layer was evaporated in vacuo, which was further purified by column chromatography on silica gel (*n*hexane/EtOAc 2:1) as eluent giving **12**.

Methyl (2S,4S)-5-allyl-N-benzyloxycarbonyl-4-fluoro-L- prolinate (12)

Colorless oil; ¹H NMR (CDCl₃) δ 1.94-3.00 (m, 4H), 3.41-4.20 (m, 4H), 4.44-4.65 (m, 1H), 4.97-5.25 (m, 3H), 5.18 (d, *J*=11.8 Hz, 1H), 5.35 (d, *J*=13.4 Hz, 1H), 5.68-5.90 (m, 1H), 7.22-7.47 (m, 5H); ¹³C NMR (CDCl₃) δ 29.66 and 31.76 (2s), 51.48 and 51.78 (2s), 52.10 (s), 58.17 (s), 67.17 (s), 69.67-70.19 (m), 109.73-110.75 (m), 116.82-121.24 (m), 127.43-128.89 (m, 5C), 134.10 (s), 136.50 (s), 160.84 (s), 171.85 (s); ¹⁹F NMR (CDCl₃) δ –173.63 (br s, 1F); IR (neat) 2953, 1757, 1709, 1436, 1354, 1213, 1175, 957, 756 cm⁻¹; HR-MS [EI (+)]: *m/z* calcd for C₁₇H₂₀FNO₄ [M⁺] 322.1376, found; 322.1361.

Demethoxycarbonylation of 12

2N NaOH (1mmol) was added to a solution of **12** (1.0 mmol) in MeOH (10 mL) and the mixture refluxed for 2 h. MeOH was removed in vacuo and the pH was adjusted to 1 with 3N HCl. The resulting suspension was extracted using EtOAc (3x 5 mL). The combined organic layer was dried using anhydrous Na_2SO_4 and evaporated to give the corresponding acid which was further dissolved in MeOH (7 mL). The resulting mixture was placed in a beaker type cell stirring at 0 °C. Then graphite anode and platinum cathode were fitted and 2,6-lutidine (1.2 mmol) was added and a constant current of 2.0 Fmol⁻¹ was passed through. The solvent was evaporated followed by addition of aqueous NaCl (7 mL). The mixture was extracted with EtOAc 3 times and the combined organic layer dried over anhydrous MgSO₄ and filtered. The solvent was removed under vacuo to give the corresponding methoxylated compound **14**. Triethylsilane (0.75 mmol) was added to a stirred solution of **14** (0.50 mmol) dissolved in dry CH₂Cl₂ (3 mL) at -78 °C under nitrogen atmosphere. The reaction was allowed to warm to 0 °C for 1 h. Methanesulfonic acid (0.60 mmol) was then added drop wise and the mixture was stirred over 30 min at room temperature. Water (20 mL) was added and the solution was extracted with CHCl₃ (3 x 10 mL). The combined organic layer was dried over anhydrous MgSO₄ and filtered. The organic layer was evaporated in vacuo and the concentrate was purified by using silica-gel column chromatography (*n*-hexane/EtOAc 2:1) as eluent giving **13** in 58% yield.

(2R,3S)-2-Allyl-N-benzyloxycarbonyl-3-fluoropyrrolidine (13)

Colorless oil; ¹H NMR (CDCl₃) δ 1.94-2.90 (m, 4H), 3.25-4.10 (m, 3H), 4.81-4.88 (m, 1H), 4.94-5.50 (m, 4H), 5.62-5.92 (m, 1H), 7.32-7.38 (m, 5H); ¹³C NMR (CDCl₃) δ 29.28 and 30.05 (2br s), 31.52 (s), 44.51 and 44.53 (2s), 61.55 and 63.02 (2br d), 66.91 (s), 89.91-92.87 (m), 117.59 (s), 117.93 (s), 127.80 (s), 127.90 and 127.95 (2s), 128.42 (s), 133.33 (br s), 134.32 (s), 136.81 (s), 154.90 (s); ¹⁹F NMR (CDCl₃) δ –187.61 and –186.68 (2br s); IR (neat) 2953, 1701, 1447, 1406, 1340, 1279, 1211, 1179, 1098, 1078, 1053, 959, 735 cm⁻¹; HR-MS [EI (+)]: *m/z* calcd for C₁₅H₁₈FNO₂ [M⁺] 263.1322, found 263.1313. HPLC YMC-Pack SIL column; 150 mm x 4.6 mm ϕ ; *n*-hexane/2-propanol 50:1, wavelength 254 nm, flow rate: 1.0 mL/min, retention time: 3.8 min (2*S*, 9%), 5.6 min (2*R*, 91%).

ACKNOWLEDGEMENTS

This research was supported by a Grant-in-Aid for Scientific Research on Innovative Areas (23105539) from The Ministry of Education, Culture, Sports, Science and Technology, a Grant-in-Aid for Scientific Research (C) (24590012) from The Japan Society for the Promotion of Science, Research Grant for Pharmaceutical Sciences from Takeda Science Foundation, and the President's Discretion Fund of Nagasaki University.

REFERENCES AND NOTES

Some representative reviews: F. J. Sardina and H. Rapoport, *Chem. Rev.*, 1996, 96, 1825; P. D. Bailey, P. A. Millwood, and P. D. Smith, *Chem. Commun.*, 1998, 633; S. Laschat and T. Dickner, *Synthesis*, 2000, 1781; A. Mitchinson and A. Nadin, *J. Chem. Soc.*, *Perkin Trans. 1*, 2000, 2862; M. D. Groaning and A. I. Meyers, *Tetrahedron*, 2000, 56, 9843; P. M. Weintraub, J. S. Sabol, J. M.

Kane, and D. R. Borcherding, *Tetrahedron*, 2003, **59**, 2953; M. G. Buffat, *Tetrahedron*, 2004, **60**, 1701.

- J. L. Castro, I. Collins, M. G. N. Russell, A. P. Watt, B. Sohal, D. Rathbone, M. S. Beer, and J. A. Stanton, *J. Med. Chem.*, 1998, 41, 2667; Y. Takeuchi, T. Tarui, and N. Shibata, *Org. Lett.*, 2000, 2, 635; P. T. Nyffeler, G. D. Sergio, D. B. Michael, P. V. Stephanne, and W. Chi-Huey, *Agnew. Chem. Int. Ed.*, 2005, 44, 192; L. Riyuan, D. Shentao, S. Zhuangzhi, and J. Ning, *Org. Lett.*, 2011, 13, 4498; C. Walpole, Z. Liu, E. E. Lee, F. Zhou, N. Mackintosh, M. Sjogren, D. Taylor, J. Shen, and R. A. Batey, *Tetrahedron Lett.*, 2012, 53, 2942.
- D. C. Lankin, N, S. Chandrakumar, S. N. Rao, D. P. Spangler, and J. P. Synder, J. Am. Chem. Soc., 1993, 115, 3356; L. Demange, A. Ménez, and C. Dugave, *Tetrahedron Lett.*, 1998, 39, 1169; J. P. Synder, N. S. Chandrakumar, H. Sato, and D. C. Lankin, J. Am. Chem. Soc., 2000, 122, 544; S. A. Golubev, S. Hartmut, R. Gabor, M. Fioroni, S. Thust, and B. Burger, *Tetrahedron Lett.*, 2004, 45, 1445; J. P. Synder, K. Hardcastle, A. Sun, and D. C. Lankin, *Chem. Eur. J.*, 2005, 11, 1579; G. Verniest, R. Surmont, E. Van Hende, A. Deweweire, D. Frederik, J. W. Thuring, and N. D. Kimpe, J. *Org. Chem.*, 2008, 73, 5458; P. K. Mykhailiuk, S. V. Shishkina, O. V. Shishkin, O. A. Zaporozhets, and I. V. Komarov, *Tetrahedron*, 2011, 67, 3091; P. S. Rajendra and T. Umemoto, J. Org. Chem., 2011, 76, 3113.
- I. Nowak, L. M. Roger, D. R. Rogers, and S. J. Thrasher, J. Fluorine Chem., 1999, 99, 73; P. S. Rajendra and M. S. Jean'ne, Acc. Chem. Res., 2004, 37, 31; A. Togni and H. Ibrahim, Chem. Commun., 2004, 1147; J. Cossy, P. D. Gomez, and I. Dechamps, Synlett, 2007, 263; L. K. Kirk, Org. Proc. Res. Dev., 2008, 12, 305; L. Hunter, Beil. J. Org. Chem., 2010, 6, 38; T. Furuya, A. S. Kamlet, and T. Ritter, Nature, 2011, 473, 470; D. Chopra, Cryst. Growth Des., 2012, 12, 541.
- Some representative reviews: J. M. Moolenaar and N. W. Speckamp, *Tetrahedron*, 2000, 56, 3817;
 A. Yazici and S. G. Pyne, *Synthesis*, 2009, 339; A. Yazici and S. G. Pyne, *Synthesis*, 2009, 513.
- T. Shono, Y. Matsumura, K. Tsubata, and K. Uchida, J. Org. Chem., 1986, 51, 2590; M. Skrinjar and L.-G. Wistrand, *Tetrahedron Lett.*, 1990, 31, 1775; T. Shono, T. Fujita, and Y. Matsumura, *Chem. Lett.*, 1991, 81; A. Rouchaud and J.-C. Braekman, *Eur. J. Org. Chem.*, 2011, 12, 2346; O. Onomura, *Heterocycles*, 2012, 85, 2111.
- R. E. Banks, *J. Fluorine Chem.*, 1998, 87, 1; Y. Takeuchi, T. Suzuki, A. Satoh, T. Shiragami, and N. Shibata, *J. Org. Chem.*, 1999, 64, 5708; A. J. Poss and G. A. Shia, *Tetrahedron Lett.*, 1999, 40, 2673; D. Cahard and C. Audouard, *Org. Lett.*, 2000, 2, 3699; B. Greedy and V. Gouverneur, *Chem. Commun.*, 2001, 233; S. Mizuta and O. Onomura, *RSC. Adv.*, 2012, 2, 2266; S. Singh, C.-M. Martinz, S. Calvet-Vitale, A. K. Prasad, T. Prangé, P. I. Dalko, and H. Dhimane, *Synlett*, 2012, 23, 2421.

- 8. T. Shono, H. Hamaguchi, and Y. Matsumura, J. Am. Chem. Soc., 1975, 97, 4264.
- 9. T. Shono, Y. Matsumura, T. Tsubata, Y. Sugihara, S. Yamane, T. Kanazawa, and T. Aoki, J. Am. Chem. Soc., 1982, 104, 6697.
- Electrophilic chlorination and bromination of 4: T. Shono, Y. Matsumura, O. Onomura, M. Ogaki, and T. Kanazawa, J. Org. Chem., 1987, 52, 536.
- 11. A. Alix, C. Lalli, P. Retailleau, and G. Masson, J. Am. Chem. Soc., 2012, 134, 10389.
- For deoxofluorination: R. P. Singh and J. M. Shreeve, *Synthesis*, 2002, 2561; F. Beaulieu, L.-P. Beauregard, G. Courchesne, M. Couturier, F. Laflamme, and A. L'Heureux, *Org. Lett.*, 2009, 11, 5050; A. L'Heureux, F. Beaulieu, C. Bennet, D. R Bill, S. Clayton, F. Laflamme, M. Mirmehrabi, S. Tadayon, D. Tovell, and M. Couturier, *J. Org. Chem.*, 2010, 75, 3401.
- O. Onomura, P. G. Kirira, T. Tanaka, S. Tsukada, Y. Matsumura, and Y. Demizu, *Tetrahedron*, 2008, 64, 7498; P. G. Kirira, M. Kuriyama, and O. Onomura, *Chem. Eur. J.*, 2010, 16, 3970; S. Hirata, M. Kuriyama, and O. Onomura, *Tetrahedron*, 2011, 67, 9411.
- C. Bucher, C. Sparr, W. B. Schweizer, and R. Gilmour, *Chem. Eur. J.*, 2009, **15**, 7637; L. E. Zimmer,
 C. Sparr, and R. Gilmour, *Angew. Chem. Int. Ed.*, 2011, **50**, 2.
- BF₃·OEt₂ mediated allylation of 3-chloro-2-methoxy-*N*-benzyloxycarbonylpiperidine gave 2-allyl-3chloro-*N*-benzyloxypiperidine in 87% de and 74% yield.

2-Allyl-3-chloro-N-benzyloxypiperidine: Colorless oil; ¹H NMR (CDCl₃) δ 1.45-1.51 (m, 1 H), 1.90-1.99 (m, 1H), 2.03-2.09 (m, 2H), 2.29-2.34 (m, 1H), 2.39-2.46 (m, 1H), 2.87 (br t, *J*=13.2 Hz, 1H), 4.15-4.21 (m, 2H), 4.57 (br t, *J*=7.7 Hz, 1H), 5.03-5.10 (m, 2H), 5.15 (s, 2H), 5.65-5.78 (m, 1H), 7.28-7.35 (m, 5H); ¹³C NMR (CDCl₃) δ 18.99 (s), 27.13 (s), 34.81 (s), 38.64 (s), 53.32 (s), 57.41 and 57.95 (2s), 67.18 (s), 117.87 (s), 127.72, 127.84 and 128.40 (3s, 5C), 133.60 (s), 136.98 (s), 155.99 (s); IR (neat) 2951, 1692, 1423, 1348, 1246, 1186, 1123, 1026, 916, 733 cm⁻¹. HR-MS [EI (+)]: *m/z* calcd for C₁₆H₂₀CINO₂ [M⁺] 293.1183, found; 293.1174. HPLC YMC-Pack SIL column; 150 mm x 4.6 mm ϕ ; *n*-hexane/2-propanol 50:1, wavelength 254 nm, flow rate: 1.0 mL/min, retention time: 2.7 min (6.3%), 3.5 min (93.7%).

- M. Köck, J. Junker, and T. Lindel, Org. Lett., 1999, 1, 2041; M. Perez-Trujillo, P. Nolis, and T. Parella, Org. Lett., 2007, 9, 29.
- J. E. Baldwin, S. J. Bamford, A. M. Fryer, and M. E. Wood, *Tetrahedron Lett.*, 1995, 36, 4869; J. E. Baldwin, S. J. Bamford, A. M. Fryer, M. P. W. Rudolph, and M. E. Wood, *Tetrahedron*, 1997, 53, 5233.
- Some literature for fluorinated cyclic amines: L. Demange, J. Cluzeau, A. Ménez, and C. Dugave, *Tetrahedron Lett.*, 2001, 42, 651; A. S. Golubev, H. Schedel, G. Radics, M. Fioroni, S. Thust, and K.

Burger, Tetrahedron Lett., 2004, 45, 1445.

- 19. Using 1.1 equiv of Lewis acids lowered the yields of allylated products 12 and 13.
- 20. L. Franck, C. Sylvain, B. Pascal, and G. Courdet, Tetrahedron, 2001, 57, 6969.
- 21. L. E. Burgess, K. M. G. Elizabeth, and J. Jurka, Tetrahedron Lett., 1996, 37, 3255.
- 22. O. Okitsu, R. Suzuki, and S. Kobayashi, J. Org. Chem., 2001, 66, 809.
- 23. S. Furukubo, N. Moriyama, O. Onomura, and Y. Matsumura, Tetrahedron Lett., 2004, 45, 8177.
- 24. W. Maison, E. Arce, P. Renold, R. J. Kennedy, and D. S. Kemp, J. Am. Chem. Soc., 2001, 123, 10245.
- 25. R. P. Singh and T. Umemoto, J. Org. Chem., 2011, 76, 3113.